적혈구제제용 백혈구제거필터 RF300의 성능평가

• Published in: Taehan Suhyŏl Hakhoe chi pp. 13 - 19
• Main Authors: 권소영, 조남선, 송순녀, 이주연, 임아현, 이현미, 지영천, 서창식, 박윤희
• Format: Journal Article
• Language: Korean
• Published: 대한수혈학회 01.04.2012
• Subjects: 임상병리학
• ISSN: 1226-9336; 2383-6881

Background:Use of universal leukoreduction for prevention of leukocyte associated transfusion reactions is common practice in many countries. This study was conducted in order to evaluate the performance of a newly developed leukoreduction filter for red blood cells (RBCs), the RF300 (Kolon Industries, Inc, Gumi, Korea). Methods:Filtration time, RBC recovery, residual leukocyte count, and leukocyte removal rate were evaluated. To assess the quality of RBCs after filtration, percent hemolysis was monitored for a period of 21 days. Performance of the RF300 (N=78) was compared with that of the Bio-R O2 plus (Fresenius, Hamburg, Germany), the Pall Purecell RC (Pall Co., Washington, USA), and the Sepacell R-500N (Asahi, Tokyo, Japan). Results:The shortest filtration time was observed using the RF300 (P＜0.05). Using the RF300, recovery of RBC was 96.5%, which was higher than that of two filters (P＜0.05). Mean residual leukocyte count was 0.26×106/unit, with a leukocyte removal rate of 3 log. Using the RF300, mean percent hemolysis was 0.32% at day 21, which was comparable with that of two filters, but lower than that of one filter (P＜0.05). Conclusion:The RF300 meets all established quality requirements for conduct of safe and effective leukoreduction of RBCs. KCI Citation Count: 0